The mechanism of immune T-cell "dryness" promoting anti-tumor effect was revealed.

The team of Professor Di Wen and researcher Deng Liufu of The Basic Clinical Collaborative Research Center of Renji Hospital affiliated with Shanghai Jiaotong University School of Medicine revealed the mechanism of "dryness" of immune T cells to promote anti-tumor effects, and provided a new strategy for enhancing the effectiveness of clinical immunotherapythe results were recently published online in Science-Translational Medicineimmunotherapy is a hot topic in the field of tumor therapy, and T-cell-based immunotherapy has encountered multiple challenges in eradicating solid tumorsdry T cells characterized by self-renewal, amplification, and pluitudes are essential for immunotherapy to achieve long-lasting anti-tumor effectsthe joint study found that cGAS-STING is important for dry CD8 plus T cells in patients with ovarian cancer, cervical cancer and endometrial cancercGAS-STING pathway is an important way to initiate the natural immune response of anti-tumor, and is expected to become a new generation of immunotherapy target simply to make tumors change from "cold" to "hot", the team used tumor models, genetics, pharmacological tools, etcto demonstrate the differentiation of cGAS-STING and type I interferon-enhanced stem cell sample CD8 plus T immune cellsSTING agonists can promote peripheral blood T-cell differentiation in healthy populations and cancer patients, and can significantly improve the efficacy of CAR-T immunotherapy solid tumorsthis study, starting from the clinical problems faced by immunotherapy, reveals that the cGAS-STING signal improves the effect of immunotherapy by maintaining the "dryness" of CD8 plus T cells, and provides a new target for the clinical design of new T-cell immunotherapyin recent years, clinical tumor immunotherapy has made breakthrough progress, in many tumors the efficacy is better than or replace the traditional chemotherapy, more and more tumor patients, including gynecological ovarian cancer, cervical cancer, endometrial cancer and other benefits from immunotherapy, this joint research has created a new direction of clinical application of tumor immunotherapy, will help to further improve the prognosis of gynecological tumor patients, improve survival rate and even achieve cure effectit is understood that the Basic Clinical Collaborative Research Center of Shanghai Jiaotong University School of Medicine aims to promote the construction of clinical disciplines, with the characteristics of combining basic research with clinical practice, and conductresearch on solving major clinical problems, and carry out original research on clinical medical problems()